Zevra Therapeutics Inc. (ZVRA)

Zevra Therapeutics (ZVRA) came out with a quarterly earnings of $1.21 per share versus the Zacks Consensus Estimate of $2.19. This compares to a loss of $0.48 per share a year ago.

Zevra Therapeutics, Inc. (NASDAQ:ZVRA ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Adrian Quartel - Chief Medical Officer Joshua M. Schafer - Chief Commercial Off...

Zevra Therapeutics (ZVRA) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of $1.43. This compares to a loss of $0.48 per share a year ago.

Zevra, Inovio and Journey Medical are set for potential earnings beat this week, backed by strong products and positive ESP scores.

Zevra Therapeutics (ZVRA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it t...

Zevra Therapeutics (ZVRA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The mean of analysts' price targets for Zevra Therapeutics (ZVRA) points to an 117.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement a...

Does Zevra Therapeutics (ZVRA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Innovation is at its peak in the Zacks Medical-Drugs industry. CPRX, ZVRA, TBPH, ALDX and LRMR may prove to be good additions to one's portfolio.

The average of price targets set by Wall Street analysts indicates a potential upside of 86.6% in Zevra Therapeutics (ZVRA). While the effectiveness of this highly sought-after metric is questionable,...